Information Library
Results for: Clinical and marketing materials - Connect with investigators, regulators and physicians - Clinical Services - Late Phase
In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions. Search our library today.
- Sort by:
- Recently Added
- Title
-
Quintiles Names New Global Head of Clinical & Data Operations
Press Release — October 6, 2011 – Quintiles announced that Steven Skolsky has been appointed Global Head of its Clinical & Data Operations (CDO) unit.
-
Clinical – Smarter Trials, Accelerated Outcomes
Brochure — February 16, 2011
Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues. -
Oversight Group Management Services - Aligned Action
Brochure — February 2, 2011
From data monitoring committees and endpoint adjudication to core laboratory oversight, Quintiles provides a one-stop solution for managing oversight groups. -
Patient Registries: A Taxonomy for the Design, Development and Implementation
Presentation — June 25, 2009
Recommendations from the ISPOR Patient Registry Classification, Strategy & Design Working Group, Team 2, for developing standard language for the characterization, classification, strategy, design, and execution of patient registries to generate data for outcomes research purposes. -
Early phase strategies
Hear from the Experts — June 15, 2009
Web cast about Early Phase Strategies. -
Risk Mitigation Programs
Brochure — April 16, 2009
Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance. -
Risk Assessment & Strategy
Brochure — April 16, 2009
Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile. -
Phase IIIb/IV Studies
Brochure — April 16, 2009
New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies. -
Late Phase and Safety Services
Brochure — April 10, 2009
Recent and pending regulatory changes have created an atmosphere of watchful waiting throughout the industry. While it may seem premature to initiate post-marketing studies to collect more “intelligent” safety data, Quintiles Late Phase & Safety Services anticipates that the need for expanded studies will soon spread.
Page 1 of 1 (9 results)

